The good news is that many of our clients feel an immediate difference
As of May 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, with a public comment period closing June 29, 2026
Body recomposition in your favor
For more information about preparing discontinuous gradients see Application Sheet C02
Challenges with GLP-1 medications Lifestyle changes are still necessary for sustainable weight loss
Risks of unsupervised use may include: Incorrect dosage or cycle length Poor product quality Contamination or sterility concerns Hormone imbalance Testosterone suppression Blood pressure changes Mood changes Fertility concerns Liver or cardiovascular strain Delayed care for an underlying condition Patients should speak with a qualified provider before using peptides, steroids, hormone therapy, or any performance-related compound